<?xml version="1.0" encoding="UTF-8"?>
<p>It is of paramount importance to quantify and include productivity gains and the wider effects in analyses of impact for vaccines with only moderate efficacy, as calculated using traditional metrics. Vaccines such as the RTS,S/AS01 malaria vaccine, CYD-TDV dengue vaccine and rotavirus vaccine used in LMIC all have limited ability to broadly protect populations over a long duration but the public health benefits were important in vaccine implementation decisions in those countries (
 <xref rid="B119" ref-type="bibr">Wilder-Smith et al., 2017</xref>). This suggests a paradigm for alternative regulatory requirements with a focus on public health outcomes (
 <xref rid="B37" ref-type="bibr">Gessner et al., 2017</xref>).
</p>
